Brief: Aura Biosciences Reports Positive Phase 2 End Of Study Results Evaluating Bel-Sar As A First-Line Treatment For Early-Stage Choroidal Melanoma
12/09/2024 11:48
Sept 12 (Reuters) - Aura Biosciences Inc AURA.O :
* AURA BIOSCIENCES REPORTS POSITIVE PHASE 2 END OF STUDY
RESULTS
EVALUATING BEL-SAR AS A FIRST-LINE TREATMENT FOR EARLY-STAGE
CHOROIDAL MELANOMA
* AURA BIOSCIENCES INC - BEL-SAR DEMONSTRATES 80% TUMOR
CONTROL
RATE, 90% VISUAL ACUITY PRESERVATION
* AURA BIOSCIENCES INC - BEL-SAR SHOWS HIGHLY FAVORABLE
SAFETY
PROFILE, NO SERIOUS ADVERSE EVENTS
Source text for Eikon: ID:nGNX7tbm1X
Further company coverage: AURA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aura Biosciences
See all newsBrief: Aura Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Aura Biosciences - May Offer Securities Up To $500 Million Aggregate
Brief: Aura Biosciences Reports Second Quarter 2026 Financial Results And Recent Business Highlights
U.S. RESEARCH ROUNDUP-Aecom, Humana, Mosaic
Aura Biosciences Q1 net loss widens on higher R&D costs